Comment From Breakthrough Breast Cancer Suggesting Women Are Missing Out On Aromatase Inhibitors, UK
Main Category: Breast CancerAlso Included In: Cancer / Oncology
Article Date: 06 Oct 2008 - 2:00 PST
email to a friend 
printer friendly 
view / write opinions 
rate articleCurrent Article Ratings:
| Patient / Public: |  |
|
| Health Professional: |  |
2 (1 votes) |
| Article Opinions: | 0 posts |
Dr Alexis Willett, Policy Manager at Breakthrough Breast Cancer, says: "This research shows that the vast majority of breast cancer specialists surveyed were confident that patients in their breast units and who could benefit from Aromatase Inhibitors (AIs) were receiving them in line with NICE guidance. However, it's vital that this is backed up by formal audits to ensure that all patients receive the best treatments for them. "
"For many breast cancer patients, tamoxifen will be the most suitable treatment. However it's important to ensure that patients who may benefit from AIs are identified."
Breakthrough Breast Cancer
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Breast Cancer headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
